Axsome Therapeutics (AXSM) Misses Q4 EPS by 92c

Axsome Therapeutics (NASDAQ: AXSM) reported Q4 EPS of ($2.08), $0.92 worse than the analyst estimate of ($1.16). Revenue for the quarter came in at $71.53 million versus the consensus estimate of $68.83 million.

For earnings history and earnings-related data on Axsome Therapeutics (AXSM) click here.

You May Also Be Interested In

• Meta capex to surge in 2027, neocloud fears ’erroneous’ - SemiAnalysis
• Piper Sandler defends Oracle ahead of earnings, sees $2.2 billion OCI upside
• Nvidia underperforms peers as report sparks rack delay worries